TG Therapeutics is a biopharmaceutical company focused on B-cell malignancies and autoimmune disease. Ublituximab is a novel, glycoengineered mAb that targets a unique epitope on the CD20 antigen. TGR-1202 is an oral, QD PI3K delta inhibitor with a differentiated safety profile. Ph 3 trial GENUINE for R/R high-risk CLL patients (IB vs. IB + ublituximab) completed and to be presented in '17. UNITY Trials combine TGR-1202 & Ublituximab. UNITY-CLL is for treatment naïve & previously treated CLL. UNITY-DLBCL is for previously treated DLBCL. Preclinical compounds include IRAK4, PDL-1, BET, GITR.